DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Röllig C, Serve H, Hüttmann A. et al.
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): A multicentre, phase 2, randomised controlled trial.
Lancet Oncol 2015;
16: 1691-1699 . doi:10.1016/S1470-2045(15)00362-9
We do not assume any responsibility for the contents of the web pages of other providers.